Bhubaneswar-based biotech startup Exsure has announced the successful closure of a ₹3 crore seed funding round led by Unicorn India Ventures. Established in 2021 by Swastika Paul and Abhishek Dutta, Exsure is at the forefront of developing innovative solutions to mitigate the adverse effects of chemotherapy through its proprietary exosome-based drug delivery platform.
Innovative Approach to Cancer Treatment
Exsure's patented platform focuses on delivering anti-cancer drugs directly to cancer and cancer stem cells using exosomes—nano-sized vesicles naturally present in the body. This targeted approach aims to:
- Reduce Toxicity: Minimize the harmful side effects commonly associated with chemotherapy.
- Prevent Relapse: Effectively target cancer stem cells to lower the chances of cancer recurrence.
- Enhance Patient Quality of Life: Improve overall survival rates and therapy outcomes for cancer patients.
Utilization of Funds
The newly acquired capital will be directed towards:
- Non-Clinical Studies: Completing essential pre-clinical research to validate the efficacy and safety of the exosome-based drug delivery system.
- Global Expansion: Promoting in-house manufactured R&D products, including Exosure, Leucosure, PlantExosure, and Dr. Berries, to international markets.
About Unicorn India Ventures
Unicorn India Ventures is a Mumbai-based early-stage venture capital firm specializing in technology-driven startups across various sectors. With a focus on nurturing innovative solutions, the firm has a track record of supporting companies that aim to make a significant impact.
Founders' Vision
Co-founders Swastika Paul and Abhishek Dutta are committed to revolutionizing cancer therapy by making high-quality, affordable treatments accessible to all. Their mission is to democratize cancer care, ensuring that advancements in medical technology translate into tangible benefits for patients worldwide.
Our Opinion on the News
Exsure's innovative approach addresses a critical need in oncology by focusing on reducing the detrimental side effects of chemotherapy. The investment from Unicorn India Ventures not only validates Exsure's groundbreaking work but also underscores the importance of supporting biotech startups dedicated to improving patient care. This funding is poised to accelerate the development and global reach of Exsure's promising therapies, potentially transforming the landscape of cancer treatment.